RBC Capital analyst Brian Abrahams downgraded Neumora Therapeutics (NMRA) to Sector Perform from Outperform with a price target of $4, down from $29.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora Therapeutics Inc trading resumes
- Neumora Therapeutics Inc trading halted, volatility trading pause
- Neumora trial failure a ‘big blow’ to bull case, says Stifel
- Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint
- Neumora down 82% after saying navacaprant did not meet primary endpoint